Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Articles online first > Minerva Cardioangiologica 2020 Sep 29

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Cardioangiologica 2020 Sep 29

DOI: 10.23736/S0026-4725.20.05196-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Dual antiplatelet therapy duration after percutaneous coronary intervention with drug-eluting stents: how short can we go?

Fausto ROCCASALVA 1, 2, Giuseppe FERRANTE 1, 2

Department of Cardiovascular Medicine, Humanitas Research Hospital, Rossano, Milan, Italy; 2 Department of
Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy


PDF


Current guidelines recommend a duration of dual antiplatelet therapy (DAPT) with aspirin and oral P2Y12 receptor inhibitors following percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) of 6 months for most patients with stable coronary disease and of 12 months for most patients with acute coronary syndromes. Large evidence from randomised clinical trials of shorter DAPT regimens after PCI with newergeneration DES is now emerging in heterogenous patient population not selected on the basis of high bleeding risk as well as in patients at high bleeding risk. The scope of this review is to provide an update on the benefits and harms of these short DAPT regimens and to discuss future directions in DAPT strategies after PCI with newer generation DES.


KEY WORDS: Dual antiplatelet therapy; Drug-eluting stents; Bleeding risk

inizio pagina